Synthesis and anticoagulant activity of bioisosteric sulfonic-Acid analogues of the antithrombin-binding pentasaccharide domain of heparin. 2012

Mihály Herczeg, and László Lázár, and Zsuzsanna Bereczky, and Katalin E Kövér, and István Timári, and János Kappelmayer, and András Lipták, and Sándor Antus, and Anikó Borbás
Research Group for Carbohydrates of the Hungarian Academy of Sciences, University of Debrecen, 4010, Debrecen, P. O. Box: 94, Hungary.

Two pentasaccharide sulfonic acids that were related to the antithrombin-binding domain of heparin were prepared, in which two or three primary sulfate esters were replaced by sodium-sulfonatomethyl moieties. The sulfonic-acid groups were formed on a monosaccharide level and the obtained carbohydrate sulfonic-acid esters were found to be excellent donors and acceptors in the glycosylation reactions. Throughout the synthesis, the hydroxy groups to be methylated were masked in the form of acetates and the hydroxy groups to be sulfated were masked with benzyl groups. The disulfonic-acid analogue was prepared in a [2+3] block synthesis by using a trisaccharide disulfonic acid as an acceptor and a glucuronide disaccharide as a donor. For the synthesis of the pentasaccharide trisulfonic acid, a more-efficient approach, which involved elongation of the trisaccharide acceptor with a non-oxidized precursor of the glucuronic acid followed by post-glycosidation oxidation at the tetrasaccharide level and a subsequent [1+4] coupling reaction, was elaborated. In vitro evaluation of the anticoagulant activity of these new sulfonic-acid derivatives revealed that the disulfonate analogue inhibited the blood-coagulation-proteinase factor Xa with outstanding efficacy; however, the introduction of the third sulfonic-acid moiety resulted in a notable decrease in the anti-Xa activity. The difference in the biological activity of the disulfonic- and trisulfonic-acid counterparts could be explained by the different conformation of their L-iduronic-acid residues.

UI MeSH Term Description Entries
D007067 Iduronic Acid Component of dermatan sulfate. Differs in configuration from glucuronic acid only at the C-5 position. Iduronate,Acid, Iduronic
D011134 Polysaccharides Long chain polymeric CARBOHYDRATES composed of MONOSACCHARIDES linked by glycosidic bonds. Glycan,Glycans,Polysaccharide
D005343 Fibrinolytic Agents Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. Antithrombic Drug,Antithrombotic Agent,Antithrombotic Agents,Fibrinolytic Agent,Fibrinolytic Drug,Thrombolytic Agent,Thrombolytic Agents,Thrombolytic Drug,Antithrombic Drugs,Fibrinolytic Drugs,Thrombolytic Drugs,Agent, Antithrombotic,Agent, Fibrinolytic,Agent, Thrombolytic,Agents, Antithrombotic,Drug, Antithrombic,Drug, Fibrinolytic,Drug, Thrombolytic,Drugs, Antithrombic
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077425 Fondaparinux Synthetic pentasaccharide that mediates the interaction of HEPARIN with ANTITHROMBINS and inhibits FACTOR Xa; it is used for prevention of VENOUS THROMBOEMBOLISM after surgery. Arixtra,Fondaparinux Sodium,Quixidar
D013451 Sulfonic Acids Inorganic or organic oxy acids of sulfur which contain the RSO2(OH) radical. Sulfonic Acid,Acid, Sulfonic,Acids, Sulfonic
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D065427 Factor Xa Inhibitors Endogenous factors and drugs that inhibit or block the activity of FACTOR XA. Direct Factor Xa Inhibitor,Direct-Acting Oral Anticoagulant,Direct-Acting Oral Anticoagulants,Factor Xa Inhibitor,Direct Factor Xa Inhibitors,Anticoagulant, Direct-Acting Oral,Anticoagulants, Direct-Acting Oral,Direct Acting Oral Anticoagulant,Direct Acting Oral Anticoagulants,Inhibitor, Factor Xa,Oral Anticoagulant, Direct-Acting,Oral Anticoagulants, Direct-Acting,Xa Inhibitor, Factor

Related Publications

Mihály Herczeg, and László Lázár, and Zsuzsanna Bereczky, and Katalin E Kövér, and István Timári, and János Kappelmayer, and András Lipták, and Sándor Antus, and Anikó Borbás
January 2012, Acta pharmaceutica Hungarica,
Mihály Herczeg, and László Lázár, and Zsuzsanna Bereczky, and Katalin E Kövér, and István Timári, and János Kappelmayer, and András Lipták, and Sándor Antus, and Anikó Borbás
November 2016, Molecules (Basel, Switzerland),
Mihály Herczeg, and László Lázár, and Zsuzsanna Bereczky, and Katalin E Kövér, and István Timári, and János Kappelmayer, and András Lipták, and Sándor Antus, and Anikó Borbás
November 1994, Bioorganic & medicinal chemistry,
Mihály Herczeg, and László Lázár, and Zsuzsanna Bereczky, and Katalin E Kövér, and István Timári, and János Kappelmayer, and András Lipták, and Sándor Antus, and Anikó Borbás
October 1976, FEBS letters,
Mihály Herczeg, and László Lázár, and Zsuzsanna Bereczky, and Katalin E Kövér, and István Timári, and János Kappelmayer, and András Lipták, and Sándor Antus, and Anikó Borbás
April 1995, Arteriosclerosis, thrombosis, and vascular biology,
Mihály Herczeg, and László Lázár, and Zsuzsanna Bereczky, and Katalin E Kövér, and István Timári, and János Kappelmayer, and András Lipták, and Sándor Antus, and Anikó Borbás
April 2022, European journal of medicinal chemistry,
Mihály Herczeg, and László Lázár, and Zsuzsanna Bereczky, and Katalin E Kövér, and István Timári, and János Kappelmayer, and András Lipták, and Sándor Antus, and Anikó Borbás
February 1994, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis,
Mihály Herczeg, and László Lázár, and Zsuzsanna Bereczky, and Katalin E Kövér, and István Timári, and János Kappelmayer, and András Lipták, and Sándor Antus, and Anikó Borbás
November 2003, Nature biotechnology,
Mihály Herczeg, and László Lázár, and Zsuzsanna Bereczky, and Katalin E Kövér, and István Timári, and János Kappelmayer, and András Lipták, and Sándor Antus, and Anikó Borbás
August 1998, Bioorganic & medicinal chemistry,
Mihály Herczeg, and László Lázár, and Zsuzsanna Bereczky, and Katalin E Kövér, and István Timári, and János Kappelmayer, and András Lipták, and Sándor Antus, and Anikó Borbás
June 1992, The Journal of biological chemistry,
Copied contents to your clipboard!